AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium

被引：0
|
作者：
Sridhar, Srikala S. [1 ]
Mackenzie, Mary J. [2 ]
Hotte, Sebastien J. [3 ]
Mukherjee, Som D. [3 ]
Murray, Nevin [4 ]
Tannock, Ian F. [1 ]
Haider, Masoom A. [1 ]
Chen, Eric X. [1 ]
Wang, Lisa [1 ]
Srinivasan, Ranuka [1 ]
Ivy, S. Percy [5 ]
Moore, Malcolm J. [1 ]
机构：
[1] Princess Margaret Hosp, Toronto, ON, Canada
[2] London Reg Canc Ctr, Toronto, ON, Canada
[3] Juravinski Canc Ctr, Hamilton, ON, Canada
[4] BC Canc Agncy, Vancouver, BC, Canada
[5] Natl Canc Inst, CTEP, Bethesda, MD USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2007年 / 6卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3337S / 3338S
页数：2
相关论文
共 50 条
  • [1] Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium
    Sridhar, S. S.
    Hotte, S. J.
    Mackenzie, M. J.
    Kollmannsberger, C.
    Haider, M. A.
    Pond, G. R.
    Chen, E. X.
    Srinivasan, R.
    Ivy, S. P.
    Moore, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium
    Sridhar, S. S.
    Mackenzie, M. J.
    Hotte, S. J.
    Mukherjee, S. D.
    Kollmannsberger, C.
    Haider, M. A.
    Chen, E. X.
    Wang, L.
    Srinivasan, R.
    Ivy, S. P.
    Moore, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Sridhar, Srikala S.
    Mackenzie, Mary J.
    Hotte, Sebastien J.
    Mukherjee, Som D.
    Tannock, Ian F.
    Murray, Nevin
    Kollmannsberger, Christian
    Haider, Masoom A.
    Chen, Eric X.
    Halford, Robert
    Wang, Lisa
    Ivy, S. Percy
    Moore, Malcolm J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2013, 31 (04) : 1008 - 1015
  • [4] A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium
    Srikala S. Sridhar
    Mary J. Mackenzie
    Sebastien J. Hotte
    Som D. Mukherjee
    Ian F. Tannock
    Nevin Murray
    Christian Kollmannsberger
    Masoom A. Haider
    Eric X. Chen
    Robert Halford
    Lisa Wang
    S. Percy Ivy
    Malcolm J. Moore
    [J]. Investigational New Drugs, 2013, 31 : 1008 - 1015
  • [5] A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial
    Hirte, H. W.
    Vidal, L.
    Fleming, G. F.
    Sugimoto, A. K.
    Morgan, R. J.
    Biagi, J. J.
    Wang, L.
    McGill, S.
    Ivy, S. P.
    Oza, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [6] Cediranib (AZD2171) in Patients With Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group Clinical Trial
    Alberts, Steven Robert
    Fitch, Tom R.
    Kim, George P.
    Morlan, Bruce W.
    Dakhil, Shaker R.
    Gross, Howard M.
    Nair, Suresh
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2012, 35 (04): : 329 - 333
  • [7] A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Sridhar, Srikala S.
    Winquist, Eric
    Eisen, Andrea
    Hotte, Sebastien J.
    McWhirter, Elaine
    Tannock, Ian F.
    Mukherjee, Som D.
    Wang, Lisa
    Blattler, Chantale
    Wright, John J.
    Moore, Malcolm J.
    [J]. INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 1045 - 1049
  • [8] A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    Srikala S. Sridhar
    Eric Winquist
    Andrea Eisen
    Sebastien J. Hotte
    Elaine McWhirter
    Ian F. Tannock
    Som D. Mukherjee
    Lisa Wang
    Chantale Blattler
    John J. Wright
    Malcolm J. Moore
    [J]. Investigational New Drugs, 2011, 29 : 1045 - 1049
  • [9] A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium
    Welch, S.
    Mackay, H. J.
    Hirte, H.
    Fleming, G. F.
    Morgan, R.
    Wang, L.
    Blattler, C.
    Ivy, S. P.
    Oza, A. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [10] Phase II trial of cediranib (AZD2171) in docetaxel-resistant, castrate-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P. M.
    Mulquin, M.
    Wright, J. J.
    Turkbey, I. B.
    Choyke, P.
    Ahlers, C. M.
    Figg, W. D.
    Dahut, W. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345